Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11426)
All Articles published online
|
Publishing Process of This Article
|
Feb 10, 2017 (publication date) through Apr 28, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 2017; 8(1): 1-20 [PMID: 28246582 DOI: 10.5306/wjco.v8.i1.1] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v8/i1/1.htm |
| Number | Citing Articles |
| 1 |
Joanna Jagieła, Piotr Bartnicki, Jacek Rysz. Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer. International Journal of Molecular Sciences 2021; 22(9): 4618 doi: 10.3390/ijms22094618
|
| 2 |
Greta Alì, Rossella Bruno, Mauro Savino, Riccardo Giannini, Serena Pelliccioni, Maura Menghi, Laura Boldrini, Agnese Proietti, Antonio Chella, Alessandro Ribechini, Gabriella Fontanini. Analysis of Fusion Genes by NanoString System: A Role in Lung Cytology?. Archives of Pathology & Laboratory Medicine 2018; 142(4): 480 doi: 10.5858/arpa.2017-0135-RA
|
| 3 |
Huan-Wei Liang, Yang Liu, Xin-Bin Pan. Treatment patterns and survival analysis in patients with unresectable stage III EGFR-mutated non-small cell lung cancer. Aging 2024; doi: 10.18632/aging.205425
|
| 4 |
AnaPeláez Bejarano, OlallaMontero Pérez. Successful treatment with durvalumab: A case report and review. Journal of Cancer Research and Therapeutics 2023; 19(2): 470 doi: 10.4103/jcrt.jcrt_1430_21
|
| 5 |
Jing Zhang, Xintong Zhang, Xiaoting Zhao, Mei Jiang, Meng Gu, Ziyu Wang, Wentao Yue. DKK1 promotes migration and invasion of non–small cell lung cancer via β-catenin signaling pathway. Tumor Biology 2017; 39(7): 101042831770382 doi: 10.1177/1010428317703820
|
| 6 |
Liuxin Wang, Weixiang Kong, Bing Liu, Xueqing Zhang. Proliferating cell nuclear antigen promotes cell proliferation and tumorigenesis by up-regulating STAT3 in non-small cell lung cancer. Biomedicine & Pharmacotherapy 2018; 104: 595 doi: 10.1016/j.biopha.2018.05.071
|
| 7 |
Yan‐Yan Li, Chun Yang, Pingting Zhou, Shijie Zhang, Yuan Yao, Dong Li. Genome‐scale analysis to identify prognostic markers and predict the survival of lung adenocarcinoma. Journal of Cellular Biochemistry 2018; 119(11): 8909 doi: 10.1002/jcb.27144
|
| 8 |
Marina C Garassino, Luis Paz-Ares, Rina Hui, Corinne Faivre-Finn, Alex Spira, David Planchard, Mustafa Özgüroğlu, Davey Daniel, David Vicente, Shuji Murakami, Corey Langer, Suresh Senan, David Spigel, Anna Rydén, Yiduo Zhang, Cathy O'Brien, Phillip A Dennis, Scott J Antonia. Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. Future Oncology 2021; 17(10): 1165 doi: 10.2217/fon-2020-1102
|
| 9 |
Yin Shi, Rui Pei, Shao Liu. Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.833773
|
| 10 |
Yoshiaki Amino, Satoru Kitazono, Shinya Uematsu, Tsukasa Hasegawa, Takahiro Yoshizawa, Ken Uchibori, Noriko Yanagitani, Atsushi Horiike, Takeshi Horai, Kazuo Kasahara, Makoto Nishio. Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC. International Journal of Clinical Oncology 2020; 25(1): 67 doi: 10.1007/s10147-019-01537-4
|
| 11 |
Paola Maria Medusa , Marina Gilli, Luca Notizia, Raffaella Pagliaro, Nicola Carro, Alessandro Moriello, Vito D'Agnano, Andrea Bianco, Fabio Perrotta, Fabiana Vitiello. Complete response to pembrolizumab as a single agent in a patient with stage III NSCLC with high PD-L1 expression: a case report. Monaldi Archives for Chest Disease 2022; doi: 10.4081/monaldi.2022.2440
|
| 12 |
Kimberly Geiger, Markus Joerger, Max Roessler, Karina Hettwer, Christoph Ritter, Kirsten Simon, Steffen Uhlig, Stefan Holdenrieder, Stefan Holdenrieder, Huub van Rossum, Michel van den Heuvel. Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy. Tumor Biology 2024; 46(s1): S191 doi: 10.3233/TUB-230014
|
| 13 |
Mohammadhadi Khorrami, Prantesh Jain, Kaustav Bera, Mehdi Alilou, Rajat Thawani, Pradnya Patil, Usman Ahmad, Sudish Murthy, Kevin Stephans, Pinfu Fu, Vamsidhar Velcheti, Anant Madabhushi. Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features. Lung Cancer 2019; 135: 1 doi: 10.1016/j.lungcan.2019.06.020
|
| 14 |
Yu Katagiri, Keiichi Jingu, Takaya Yamamoto, Haruo Matsushita, Rei Umezawa, Yojiro Ishikawa, Noriyoshi Takahashi, Kazuya Takeda, Shun Tasaka, Noriyuki Kadoya. Differences in patterns of recurrence of squamous cell carcinoma and adenocarcinoma after radiotherapy for stage III non-small cell lung cancer. Japanese Journal of Radiology 2021; 39(6): 611 doi: 10.1007/s11604-021-01091-y
|
| 15 |
Maura R. Vrabel, Jacob A. Schulman, Francis B. Gillam, Siena M. Mantooth, Khue G. Nguyen, David A. Zaharoff. Focal Cryo-Immunotherapy with Intratumoral IL-12 Prevents Recurrence of Large Murine Tumors. Cancers 2023; 15(8): 2210 doi: 10.3390/cancers15082210
|
| 16 |
Shantelle Smith, Daniel Sapkaroski, Margaret Brand, Anh Tran, John Zalcberg, Robert G. Stirling. Mapping the clinical care pathways for advanced stage non‐small cell lung cancer patients in Victoria: A retrospective cohort study of supportive and palliative care. Nursing & Health Sciences 2023; 25(3): 411 doi: 10.1111/nhs.13044
|
| 17 |
Wan Ling Tan, Kevin L.M. Chua, Chia-Chi Lin, Victor H.F. Lee, Lye Mun Tho, Anthony W. Chan, Gwo Fuang Ho, Thanyanan Reungwetwattana, James C. Yang, Dong-Wan Kim, Ross A. Soo, Yong Chan Ahn, Hiroshi Onishi, Myung-Ju Ahn, Tony S.K. Mok, Daniel S.W. Tan, Fan Yang. Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. Journal of Thoracic Oncology 2020; 15(3): 324 doi: 10.1016/j.jtho.2019.10.022
|
| 18 |
David R. Spigel, Corinne Faivre-Finn, Jhanelle E. Gray, David Vicente, David Planchard, Luis Paz-Ares, Johan F. Vansteenkiste, Marina C. Garassino, Rina Hui, Xavier Quantin, Andreas Rimner, Yi-Long Wu, Mustafa Özgüroğlu, Ki H. Lee, Terufumi Kato, Maike de Wit, Takayasu Kurata, Martin Reck, Byoung C. Cho, Suresh Senan, Jarushka Naidoo, Helen Mann, Michael Newton, Piruntha Thiyagarajah, Scott J. Antonia. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. Journal of Clinical Oncology 2022; 40(12): 1301 doi: 10.1200/JCO.21.01308
|
| 19 |
Wang Jing, Ting Xu, Lirong Wu, Pablo B. Lopez, Clemens Grassberger, Susannah G. Ellsworth, Radhe Mohan, Brian P. Hobbs, George R. Blumenschein, Janet Tu, Mehmet Altan, Percy Lee, Zhongxing Liao, Steven H. Lin. Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC. JTO Clinical and Research Reports 2022; 3(9): 100391 doi: 10.1016/j.jtocrr.2022.100391
|
| 20 |
Yuan Zheng, Wei Zhu, Xinjie Huang, Dongqun Lin, Yu Lin. Neoadjuvant immunotherapy combined with chemotherapy for locally advanced squamous cell lung carcinoma: A case report and literature review. Open Life Sciences 2021; 16(1): 838 doi: 10.1515/biol-2021-0083
|
| 21 |
Mumtaz V. Rojiani, Amyn M. Rojiani. Non-Small Cell Lung Cancer—Tumor Biology. Cancers 2024; 16(4): 716 doi: 10.3390/cancers16040716
|
| 22 |
Neha Pathak, Sindhura Chitikela, Prabhat Singh Malik. . Advances in Genetics 2021; 108: 201 doi: 10.1016/bs.adgen.2021.08.004
|
| 23 |
Ullas Batra, Kumar Prabhash, Jai Prakash Agarwal, Laleng Darlong, Anusheel Munshi, Prasanth Penumadu, Balamugesh Thangakunam, Abhishek Bansal. Clinical management of stage III non‐small cell lung cancer in India: An expert consensus statement. Asia-Pacific Journal of Clinical Oncology 2023; 19(6): 606 doi: 10.1111/ajco.13938
|
| 24 |
Yan Li, Kum-Hee Yun, Hyeri Lee, Sung-Ho Goh, Yang-Gun Suh, Yongdoo Choi. Porous platinum nanoparticles as a high-Z and oxygen generating nanozyme for enhanced radiotherapy in vivo. Biomaterials 2019; 197: 12 doi: 10.1016/j.biomaterials.2019.01.004
|
| 25 |
Xiaobo Cheng, Jing Wang, Chenli Qiu, Yanling Jin, Bili Xia, Ran Qin, Huiliang Hu, Jia Yan, Xiaoyan Zhang, Jianqing Xu. Feasibility of iNKT cell and PD-1+CD8+ T cell-based immunotherapy in patients with lung adenocarcinoma: Preliminary results of a phase I/II clinical trial. Clinical Immunology 2022; 238: 108992 doi: 10.1016/j.clim.2022.108992
|
| 26 |
Juliette Degens, D De Ruysscher, Ruud Houben, Bastiaan Kietselaer, Gerben Bootsma, Lizza Hendriks, Ellen Huijbers, Annemie Schols, Anne-Marie C Dingemans. Are patients with stage III non-small cell lung cancer treated with chemoradiotherapy at risk for cardiac events? Results from a retrospective cohort study. BMJ Open 2020; 10(9): e036492 doi: 10.1136/bmjopen-2019-036492
|
| 27 |
Priyanka Bobbili, Kellie Ryan, Maral DerSarkissian, Akanksha Dua, Christopher Yee, Mei Sheng Duh, Jorge E. Gomez, Jason Chia-Hsun Hsieh. Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer. PLOS ONE 2020; 15(3): e0230444 doi: 10.1371/journal.pone.0230444
|
| 28 |
Kazumasa Ogawa, Yui Takahashi, Kyoko Murase, Shigeo Hanada, Hironori Uruga, Hisashi Takaya, Atsushi Miyamoto, Nasa Morokawa, Atsuko Kurosaki, Kazuma Kishi. Treatment outcome of patients with unresectable stage III non-small cell lung cancer and interstitial pneumonia. Respiratory Investigation 2019; 57(4): 388 doi: 10.1016/j.resinv.2019.02.004
|
| 29 |
Jerold Loh, Jia Li Low, Manavi Sachdeva, Peter QJ Low, Rachel Su Jen Wong, Yiqing Huang, Puey Ling Chia, Ross A Soo. Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer. Expert Review of Anticancer Therapy 2023; 23(9): 913 doi: 10.1080/14737140.2023.2245140
|
| 30 |
Abdul Rahman Jazieh, Huseyin Cem Onal, Daniel Shao Weng Tan, Ross A. Soo, Kumar Prabhash, Amit Kumar, Reto Huggenberger, Stephen Robb, Byoung-Chul Cho. Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study. Journal of Thoracic Oncology 2021; 16(10): 1733 doi: 10.1016/j.jtho.2021.05.003
|
| 31 |
HongBo Su, GuanZhi Fan, Jin Huang, XueShan Qiu. LncRNA HOXC-AS3 promotes non-small-cell lung cancer growth and metastasis through upregulation of YBX1. Cell Death & Disease 2022; 13(4) doi: 10.1038/s41419-022-04723-x
|
| 32 |
Shadi Hamouri, Nasr Alrabadi, Sebawe Syaj, Hassan Abushukair, Obada Ababneh, Leen Al-Kraimeen, Majd Al-Sous, Erich Hecker. Atrial resection for T4 non-small cell lung cancer with left atrium involvement: a systematic review and meta-analysis of survival. Surgery Today 2023; 53(3): 279 doi: 10.1007/s00595-021-02446-8
|
| 33 |
Ranpu Wu, Shaorong Yu, Jinjun Ye, Yimin Wang, Zhiting Zhao, Hongbing Liu, Yong Song. A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.692703
|
| 34 |
Mario Ouwens, Annie Darilay, Yiduo Zhang, Pralay Mukhopadhyay, Helen Mann, James Ryan, Phillip A. Dennis. Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study. Current Therapeutic Research 2021; 95: 100640 doi: 10.1016/j.curtheres.2021.100640
|
| 35 |
Patrizia Ciammella, Salvatore Cozzi, Paolo Borghetti, Marco Galaverni, Valerio Nardone, Maria Paola Ruggieri, Matteo Sepulcri, Vieri Scotti, Alessio Bruni, Francesca Zanelli, Roberto Piro, Elena Tagliavini, Andrea Botti, Federico Iori, Emanuele Alì, Chiara Bennati, Marcello Tiseo. Redetermination of PD-L1 expression after chemio-radiation in locally advanced PDL1 negative NSCLC patients: retrospective multicentric analysis. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1325249
|
| 36 |
Tadashi Sakaguchi, Kentaro Ito, Naoki Furuya, Kei Morikawa, Kentaro Fujiwara, Yoichi Nishii, Takeo Inoue, Osamu Hataji, Masamichi Mineshita. Assessment of chemotherapy regimens on radiation pneumonitis in patients with unresectable stage III non‐small‐cell lung cancer after definitive chemoradiotherapy. Thoracic Cancer 2021; 12(13): 2024 doi: 10.1111/1759-7714.14005
|
| 37 |
Nobuyuki Yamamoto, Hideyuki Harada, Isamu Okamoto, Noriyuki Masuda, Kazushige Hayakawa, Miyako Satouchi, Toshinori Soejima, Makoto Nishio, Takuyo Kozuka, Koji Takeda, Masahiro Tanaka, Takashi Seto, Tomonari Sasaki, Hiroshi Tsubouchi, Yasuyuki Kakurai, Yasumasa Nishimura, Kazuhiko Nakagawa. Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2021; 22(2): 134 doi: 10.1016/j.cllc.2020.12.012
|
| 38 |
Suna Zhou, Yinnan Meng, Xuefeng Sun, Zhicheng Jin, Wei Feng, Haihua Yang. The critical components for effective adaptive radiotherapy in patients with unresectable non-small-cell lung cancer: who, when and how. Future Oncology 2022; 18(31): 3551 doi: 10.2217/fon-2022-0291
|
| 39 |
Muhammet Ali BEYOGLU, Selim Şakir Erkmen GULHAN, Ayperi ÖZTÜRK, Leyla Nesrin ACAR, Mehmet ŞAHİN, Gokturk FİNDİK. The Survival Efficiency of Initial Surgical Treatment in Stage IIIa-N2 Positive Non-Small Cell Lung Cancer. Middle Black Sea Journal of Health Science 2021; 7(3): 416 doi: 10.19127/mbsjohs.981036
|
| 40 |
Amanda M. Moore, Zohra Nooruddin, Kelly R. Reveles, Paromita Datta, Jennifer M. Whitehead, Kathleen Franklin, Munaf Alkadimi, Madison H. Williams, Ryan A. Williams, Sarah Smith, Renee Reichelderfer, Ion Cotarla, Lance Brannman, Andrew Frankart, Tiernan Mulrooney, Kristin Hsieh, Daniel J. Simmons, Xavier Jones, Christopher R. Frei. Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study. Current Oncology 2023; 30(9): 8411 doi: 10.3390/curroncol30090611
|
| 41 |
Brett H. Diamond, Neel Belani, Rebecca Masel, Kathryn DeCarli, Thomas DiPetrillo, Jaroslaw T. Hepel, Christopher G. Azzoli, Humera Khurshid, Abbas Abbas, Paul P. Koffer. Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab. Advances in Radiation Oncology 2023; 8(2): 101130 doi: 10.1016/j.adro.2022.101130
|
| 42 |
Julian Taugner, Lukas Käsmann, Chukwuka Eze, Amanda Tufman, Niels Reinmuth, Thomas Duell, Claus Belka, Farkhad Manapov. Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting. Cancers 2021; 13(7): 1613 doi: 10.3390/cancers13071613
|
| 43 |
Chuan-Hsin Chang, Yue-Cune Chang. Comparing the Therapeutic Efficacies of Lung Cancer: Network Meta-Analysis Approaches. International Journal of Environmental Research and Public Health 2022; 19(21): 14324 doi: 10.3390/ijerph192114324
|
| 44 |
Jarushka Naidoo, Johan F. Vansteenkiste, Corinne Faivre-Finn, Mustafa Özgüroğlu, Shuji Murakami, Rina Hui, Xavier Quantin, Helen Broadhurst, Michael Newton, Piruntha Thiyagarajah, Scott J. Antonia. Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. Lung Cancer 2022; 166: 84 doi: 10.1016/j.lungcan.2022.02.003
|
| 45 |
Yatong Zhang, Yumei Tian, Li Zheng, Xuelin Sun, Zinan Zhao, Yujing Zheng, Jinhui Tian. Efficacy and safety of consolidation durvalumab after chemoradiation therapy for stage III non-small-cell lung cancer: a systematic review, meta-analysis, and meta-regression of real-world studies. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1103927
|
| 46 |
Jun-Chieh J. Tsay, Benjamin G. Wu, Imran Sulaiman, Katherine Gershner, Rosemary Schluger, Yonghua Li, Ting-An Yie, Peter Meyn, Evan Olsen, Luisannay Perez, Brendan Franca, Joseph Carpenito, Tadasu Iizumi, Mariam El-Ashmawy, Michelle Badri, James T. Morton, Nan Shen, Linchen He, Gaetane Michaud, Samaan Rafeq, Jamie L. Bessich, Robert L. Smith, Harald Sauthoff, Kevin Felner, Ray Pillai, Anastasia-Maria Zavitsanou, Sergei B. Koralov, Valeria Mezzano, Cynthia A. Loomis, Andre L. Moreira, William Moore, Aristotelis Tsirigos, Adriana Heguy, William N. Rom, Daniel H. Sterman, Harvey I. Pass, Jose C. Clemente, Huilin Li, Richard Bonneau, Kwok-Kin Wong, Thales Papagiannakopoulos, Leopoldo N. Segal. Lower Airway Dysbiosis Affects Lung Cancer Progression. Cancer Discovery 2021; 11(2): 293 doi: 10.1158/2159-8290.CD-20-0263
|
| 47 |
Jun Gong, Thang Q. Le, Erminia Massarelli, Andrew E. Hendifar, Richard Tuli. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. Journal for ImmunoTherapy of Cancer 2018; 6(1) doi: 10.1186/s40425-018-0361-7
|
| 48 |
Changjun He, Xue Bai, Yingbin Li, Haobo Sun, Xianglong Kong, Bicheng Fu, Lantao Chen, Kaibin Zhu, Pengju Li, Shidong Xu. Runt-related transcription factor 1 contributes to lung cancer development by binding to tartrate-resistant acid phosphatase 5. Cell Cycle 2019; 18(23): 3404 doi: 10.1080/15384101.2019.1678966
|
| 49 |
Yan Cui, Xuena Li, Bulin Du, Yao Diao, Yaming Li. <p>PD-L1 in Lung Adenocarcinoma: Insights into the Role of <sup>18</sup>F-FDG PET/CT</p>. Cancer Management and Research 2020; : 6385 doi: 10.2147/CMAR.S256871
|
| 50 |
Yuting Kuang, Christine M. Pierce, Hsiu-Ching Chang, Alexandra Z. Sosinsky, Anne C. Deitz, Steven M. Keller, Ayman Samkari, Jennifer Uyei. Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: A systematic literature review and meta-analysis. Lung Cancer 2022; 174: 174 doi: 10.1016/j.lungcan.2022.06.005
|
| 51 |
Jarushka Naidoo, Mizuki Nishino, Sandip Pravin Patel, Bairavi Shankar, Natasha Rekhtman, Peter Illei, Phillipe Camus. Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2020; 21(5): e435 doi: 10.1016/j.cllc.2020.02.025
|
| 52 |
Khalid Jazieh, Mohammadhadi Khorrami, Anas Saad, Mohamed Gad, Amit Gupta, Pradnya Patil, Vidya Sankar Viswanathan, Prabhakar Rajiah, Charles J Nock, Michael Gilkey, Pingfu Fu, Nathan A Pennell, Anant Madabhushi. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab. Journal for ImmunoTherapy of Cancer 2022; 10(3): e003778 doi: 10.1136/jitc-2021-003778
|
| 53 |
Da Som Jeon, Ho Cheol Kim, Se Hee Kim, Tae-Jung Kim, Hong Kwan Kim, Mi Hyung Moon, Kyongmin Sarah Beck, Yang-Gun Suh, Changhoon Song, Jin Seok Ahn, Jeong Eun Lee, Jeong Uk Lim, Jae Hyun Jeon, Kyu-Won Jung, Chi Young Jung, Jeong Su Cho, Yoo-Duk Choi, Seung-Sik Hwang, Chang-Min Choi. Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015. Cancer Research and Treatment 2023; 55(1): 103 doi: 10.4143/crt.2022.264
|
| 54 |
Juliana Machado-Rugolo, Alexandre Todorovic Fabro, Daniel Ascheri, Cecília Farhat, Alexandre Muxfeldt Ab'Saber, Vanessa Karen de Sá, Maria Aparecida Nagai, Teresa Takagaki, Ricardo Terra, Edwin Roger Parra, Vera Luiza Capelozzi. Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non–small cell lung cancer. Human Pathology 2019; 83: 177 doi: 10.1016/j.humpath.2018.08.026
|
| 55 |
Chih-Yen Chang, Yen-Chiao (Angel) Lu, Wen-Chien Ting, Tsu-Wang (David) Shen, Wen-Chen Peng. An artificial immune system with bootstrap sampling for the diagnosis of recurrent endometrial cancers. Open Medicine 2021; 16(1): 237 doi: 10.1515/med-2021-0226
|
| 56 |
Angela Sardaro, Fiona McDonald, Lilia Bardoscia, Konstantin Lavrenkov, Shalini Singh, Sue Ashley, Daphne Traish, Cristina Ferrari, Icro Meattini, Artor Niccoli Asabella, Michael Brada. Dyspnea in Patients Receiving Radical Radiotherapy for Non-Small Cell Lung Cancer: A Prospective Study. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.594590
|
| 57 |
Hiroshi Mayahara, Kazuyuki Uehara, Aya Harada, Keiji Kitatani, Tomonori Yabuuchi, Shuichirou Miyazaki, Takeaki Ishihara, Hiroki Kawaguchi, Hikaru Kubota, Hideaki Okada, Taira Ninomaru, Chihiro Shindo, Akito Hata. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer. Radiation Oncology 2022; 17(1) doi: 10.1186/s13014-021-01979-z
|
| 58 |
Ajab Shereen, Kastelik Jack A, Loubani Mahmoud. Current medical and surgical management of lung cancer. Journal of Surgery and Surgical Research 2021; : 052 doi: 10.17352/2455-2968.000137
|
| 59 |
Martin Wilhelm. Durvalumab nach einer Radiochemotherapie ist beim NSCLC im Stadium III derzeit die vielversprechendste Therapie. Strahlentherapie und Onkologie 2019; 195(7): 691 doi: 10.1007/s00066-019-01456-3
|
| 60 |
Federica Sotgia, Michael P. Lisanti. Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients: Use as companion diagnostics. Oncotarget 2017; 8(40): 68095 doi: 10.18632/oncotarget.19677
|
| 61 |
L. Nicosia, L. Agolli, C. Reverberi, V. De Sanctis, L. Marinelli, G. Minniti, J. Di Muzio, M. Valeriani, M. F. Osti. Salvage radiotherapy with simultaneous integrated boost in non small-cell lung cancer patients with mediastinal relapse after surgery: a pilot study. Radiation Oncology 2018; 13(1) doi: 10.1186/s13014-018-1155-2
|
| 62 |
Yang Liu, Huan-Wei Liang, Xin-Bin Pan. Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients. Aging 2023; doi: 10.18632/aging.204781
|
| 63 |
Scott J. Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki H. Lee, Maike de Wit, Byoung C. Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young-Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz-Ares, Javier de Castro Carpeño, Corinne Faivre-Finn, Martin Reck, Johan Vansteenkiste, David R. Spigel, Catherine Wadsworth, Giovanni Melillo, Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of Medicine 2018; 379(24): 2342 doi: 10.1056/NEJMoa1809697
|
| 64 |
Carsten Brink, Uffe Bernchou, Anders Bertelsen, Olfred Hansen, Tine Schytte, Jacob v.B. Hjelmborg, Lois Holloway, Marcel van Herk, Corinne Johnson-Hart, Gareth J. Price, Marianne C. Aznar, Alan McWilliam, Corinne Faivre-Finn, Christian R. Hansen. Causal relation between heart irradiation and survival of lung cancer patients after radiotherapy. Radiotherapy and Oncology 2022; 172: 126 doi: 10.1016/j.radonc.2022.05.002
|
| 65 |
Maria Mitsogianni, Nikolaos Mitsimponas, Felipe Crespo, Karl Axel Hartmann, Bernd Klosterhalfen, Sabine Haase, Aristoteles Giagounidis. Concomitant Non-Small Cell Lung Cancer and Hairy Cell Leukemia in a Patient Harboring BRAF-V600E Mutation in Both Tissues: A Case Report. Case Reports in Oncology 2018; 11(1): 109 doi: 10.1159/000486640
|
| 66 |
Eriko Miyawaki, Hirotsugu Kenmotsu, Yasushi Shintani, Ikuo Sekine, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Kazuhisa Takahashi, Nobuyuki Yamamoto, Tomoya Kawaguchi, Etsuo Miyaoka, Ichiro Yoshino, Hiroshi Date. Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study. BMC Cancer 2022; 22(1) doi: 10.1186/s12885-022-09441-3
|
| 67 |
Priyanka Bobbili, Kellie Ryan, Mei S Duh, Akanksha Dua, Ancilla W Fernandes, Melissa Pavilack, Jorge E Gomez. Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer. Future Oncology 2019; 15(29): 3381 doi: 10.2217/fon-2019-0282
|
| 68 |
Yanan Zhang, Zhehui Liu, Hongmin Wang, Fengfan Liang, Liqiong Zhu, Haifeng Liu. Association of metastatic nodal size with survival in non-surgical non-small cell lung cancer patients: Recommendations for clinical N staging. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.990540
|
| 69 |
Kevin Lu, Brian D. Woodward, Joshua Boys, Mark Onaitis, Hatim Husain. Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC. Clinical Lung Cancer 2024; 25(1): e58 doi: 10.1016/j.cllc.2023.08.012
|
| 70 |
G. Daniel Grass, Arash O. Naghavi, Yazan A. Abuodeh, Bradford A. Perez, Thomas J. Dilling. Analysis of Relapse Events After Definitive Chemoradiotherapy in Locally Advanced Non–Small-Cell Lung Cancer Patients. Clinical Lung Cancer 2019; 20(1): e1 doi: 10.1016/j.cllc.2018.08.009
|
| 71 |
Yuko Kawano, Tomonari Sasaki, Hiroyuki Yamaguchi, Katsuya Hirano, Atsushi Horiike, Miyako Satouchi, Shinobu Hosokawa, Ryotaro Morinaga, Kazutoshi Komiya, Koji Inoue, Yuka Fujita, Ryo Toyozawa, Tomoki Kimura, Kosuke Takahashi, Kazuo Nishikawa, Junji Kishimoto, Yoichi Nakanishi, Isamu Okamoto. Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non–small cell lung cancer. Lung Cancer 2018; 125: 136 doi: 10.1016/j.lungcan.2018.09.014
|
| 72 |
Howard West, Xiaohan Hu, Su Zhang, Yan Song, Diana Chirovsky, Chi Gao, Ariel Lerner, Anya Jiang, James Signorovitch, Ayman Samkari. Treatment Patterns and Outcomes in Resected Early-stage Non-small Cell Lung Cancer: An Analysis of the SEER-Medicare Data. Clinical Lung Cancer 2023; 24(3): 260 doi: 10.1016/j.cllc.2022.12.005
|
| 73 |
Duygu Sezen, Hampartsoum B. Barsoumian, Kewen He, Yun Hu, Qi Wang, Chike O. Abana, Nahum Puebla-Osorio, Ethan Y. Hsu, Mark Wasley, Fatemeh Masrorpour, Jing Wang, Maria Angelica Cortez, James W. Welsh. Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.984318
|
| 74 |
Giulia Veronesi, Pierluigi Novellis, Emanuele Voulaz, Pietro Bruschini. Robotic assisted lung resection for locally advanced lung cancer. Expert Review of Respiratory Medicine 2020; 14(2): 121 doi: 10.1080/17476348.2020.1697235
|
| 75 |
Joanna Pancewicz, Wiesława Ewa Niklińska, Adrian Chlanda. Flake Graphene-Based Nanomaterial Approach for Triggering a Ferroptosis as an Attractive Theranostic Outlook for Tackling Non-Small Lung Cancer: A Mini Review. Materials 2022; 15(10): 3456 doi: 10.3390/ma15103456
|
| 76 |
Corinne Faivre-Finn, David Vicente, Takayasu Kurata, David Planchard, Luis Paz-Ares, Johan F. Vansteenkiste, David R. Spigel, Marina C. Garassino, Martin Reck, Suresh Senan, Jarushka Naidoo, Andreas Rimner, Yi-Long Wu, Jhanelle E. Gray, Mustafa Özgüroğlu, Ki H. Lee, Byoung C. Cho, Terufumi Kato, Maike de Wit, Michael Newton, Lu Wang, Piruntha Thiyagarajah, Scott J. Antonia. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial. Journal of Thoracic Oncology 2021; 16(5): 860 doi: 10.1016/j.jtho.2020.12.015
|
| 77 |
Nobuaki Mamesaya, Koji Muramatsu, Michitoshi Yabe, Hiroaki Kodama, Naoya Nishioka, Taichi Miyawaki, Eriko Miyawaki, Haruki Kobayashi, Shota Omori, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Hideyuki Harada, Takashi Sugino, Tetsuo Shimizu, Yasuhiro Gon, Toshiaki Takahashi. Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy. International Journal of Clinical Oncology 2021; 26(4): 659 doi: 10.1007/s10147-020-01856-x
|
| 78 |
Ida Kappel Buhl, Eric Santoni-Rugiu, Jesper Ravn, Anker Hansen, Ib Jarle Christensen, Thomas Jensen, Bruce Pratt, Jon Askaa, Peter Buhl Jensen, Steen Knudsen, Jens Benn Sørensen, Aamir Ahmad. Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)—validation in two independent cohorts. PLOS ONE 2018; 13(3): e0194609 doi: 10.1371/journal.pone.0194609
|
| 79 |
Kazutaka Hosoya, Daichi Fujimoto, Hayato Kawachi, Yuki Sato, Mariko Kogo, Kazuma Nagata, Atsushi Nakagawa, Ryo Tachikawa, Shinya Hiraoka, Masaki Kokubo, Keisuke Tomii. Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients. Cancer Chemotherapy and Pharmacology 2019; 84(2): 275 doi: 10.1007/s00280-019-03885-4
|
| 80 |
Xabier Mielgo-Rubio, Federico Rojo, Laura Mezquita-Pérez, Francesc Casas, Amadeo Wals, Manel Juan, Carlos Aguado, Javier Garde-Noguera, David Vicente, Felipe Couñago. Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck. World Journal of Clinical Oncology 2020; 11(11): 898-917 doi: 10.5306/wjco.v11.i11.898
|
| 81 |
Shigeru Tanzawa, Tomonori Makiguchi, Sadatomo Tasaka, Megumi Inaba, Ryosuke Ochiai, Junya Nakamura, Koji Inoue, Takayuki Kishikawa, Masanao Nakashima, Keiichi Fujiwara, Tadashi Kohyama, Hiroo Ishida, Shoichi Kuyama, Naoki Miyazawa, Tomomi Nakamura, Hiroshi Miyawaki, Naohiro Oda, Nobuhisa Ishikawa, Ryotaro Morinaga, Kei Kusaka, Yosuke Miyamoto, Toshihide Yokoyama, Chiaki Matsumoto, Takeshi Tsuda, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Toshihiro Misumi, Kenshiro Shiraishi, Noriyuki Matsutani, Nobuhiko Seki. Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study). Therapeutic Advances in Medical Oncology 2022; 14: 175883592211166 doi: 10.1177/17588359221116603
|
| 82 |
Martin J Edelman. The PACIFIC Trial—Where Do We Go from Here in Immunotherapy for Non-small Cell Lung Cancer?. Oncology & Hematology Review (US) 2018; 14(2): 65 doi: 10.17925/OHR.2018.14.2.65
|
| 83 |
Diem Vuong, Marta Bogowicz, Leonard Wee, Oliver Riesterer, Eugenia Vlaskou Badra, Louisa Abigail D’Cruz, Panagiotis Balermpas, Janita E. van Timmeren, Simon Burgermeister, André Dekker, Dirk De Ruysscher, Jan Unkelbach, Sandra Thierstein, Eric I. Eboulet, Solange Peters, Miklos Pless, Matthias Guckenberger, Stephanie Tanadini-Lang. Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-00239-0
|
| 84 |
Nikolaos F Pistamaltzian, Vassilis Georgoulias, Athanasios Kotsakis. The role of immune checkpoint inhibitors in advanced non-small cell lung cancer. Expert Review of Respiratory Medicine 2019; 13(5): 435 doi: 10.1080/17476348.2019.1593828
|
| 85 |
Christoph Grohmann, Francesca Walker, Mark Devlin, Meng-Xiao Luo, Anderly C. Chüeh, Judy Doherty, François Vaillant, Gwo-Yaw Ho, Matthew J. Wakefield, Clare E. Weeden, Alvin Kamili, Jayne Murray, Sela T. Po’uha, Janet Weinstock, Serena R. Kane, Maree C. Faux, Esmee Broekhuizen, Ye Zheng, Kristy Shield-Artin, Nadia J. Kershaw, Chin Wee Tan, Helen M. Witchard, Gregor Ebert, Susan A. Charman, Ian Street, Maria Kavallaris, Michelle Haber, Jamie I. Fletcher, Marie-Liesse Asselin-Labat, Clare L. Scott, Jane E. Visvader, Geoffrey J. Lindeman, Keith G. Watson, Antony W. Burgess, Guillaume Lessene. Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors. Cell Death & Disease 2021; 12(3) doi: 10.1038/s41419-020-03269-0
|
| 86 |
Dennis Jun Jie Poon, Li Min Tay, Dean Ho, Melvin Lee Kiang Chua, Edward Kai-Hua Chow, Eugenia Li Ling Yeo. Improving the therapeutic ratio of radiotherapy against radioresistant cancers: Leveraging on novel artificial intelligence-based approaches for drug combination discovery. Cancer Letters 2021; 511: 56 doi: 10.1016/j.canlet.2021.04.019
|
| 87 |
Adithya Balasubramanian, James Onggo, Ashray Gunjur, Thomas John, Sagun Parakh. Immune Checkpoint Inhibition With Chemoradiotherapy in Stage III Non–small-cell Lung Cancer: A Systematic Review and Meta-analysis of Safety Results. Clinical Lung Cancer 2021; 22(2): 74 doi: 10.1016/j.cllc.2020.10.023
|
| 88 |
Jihane Boustani, Elodie Lauret Marie Joseph, Etienne Martin, Salim Benhmida, Benoit Lecoester, Florent Tochet, Céline Mirjolet, Cédric Chevalier, David Thibouw, Noémie Vulquin, Stéphanie Servagi, Xushan Sun, Olivier Adotévi. Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood. BMC Immunology 2021; 22(1) doi: 10.1186/s12865-021-00429-5
|
| 89 |
Faizan Haider Khan, Malik Johid Reza, Yusra Fatima Shao, Ahmad Perwez, Honey Zahra, Afshin Dowlati, Ata Abbas. Role of exosomes in lung cancer: A comprehensive insight from immunomodulation to theragnostic applications. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2022; 1877(5): 188776 doi: 10.1016/j.bbcan.2022.188776
|
| 90 |
Narjust Duma, Rafael Santana-Davila, Julian R. Molina. Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clinic Proceedings 2019; 94(8): 1623 doi: 10.1016/j.mayocp.2019.01.013
|
| 91 |
Seema Kumari, Deme Karikios, Roland Yeghiaian‐Alvandi, Peter Flynn, Lucy Morgan, Lisa Kay, Pei Ding. Treatment patterns and long‐term survival outcomes for patients with stage III non‐small cell lung cancer: A retrospective study. Asia-Pacific Journal of Clinical Oncology 2024; 20(1): 25 doi: 10.1111/ajco.13937
|
| 92 |
M. F. Mridha, Akibur Rahman Prodeep, A. S. M. Morshedul Hoque, Md. Rashedul Islam, Aklima Akter Lima, Muhammad Mohsin Kabir, Md. Abdul Hamid, Yutaka Watanobe, Rafael Morales. A Comprehensive Survey on the Progress, Process, and Challenges of Lung Cancer Detection and Classification. Journal of Healthcare Engineering 2022; 2022: 1 doi: 10.1155/2022/5905230
|
| 93 |
YANG ZHANG, LIXIA MA, TINGTING ZHANG, PEIDONG LI, JIABIN XU, ZHUO WANG. Long Noncoding RNA TFAP2A-AS1 Exerts Promotive Effects in Non-Small Cell Lung Cancer Progression Via Controlling the microRNA-548a-3p/CDK4 axis as a Competitive Endogenous RNA. Oncology Research 2021; 29(2): 129 doi: 10.32604/or.2022.03563
|
| 94 |
Aditya Juloori, Everett E. Vokes. Beyond PACIFIC: Uncharted Waters. Journal of Thoracic Oncology 2021; 16(5): 715 doi: 10.1016/j.jtho.2021.02.006
|
| 95 |
Salma K. Jabbour, Ki Hyeong Lee, Nikolaj Frost, Valeriy Breder, Dariusz M. Kowalski, Theodore Pollock, Evgeny Levchenko, Noemi Reguart, Alex Martinez-Marti, Baerin Houghton, Jean-Baptiste Paoli, Sufia Safina, Keunchil Park, Takefumi Komiya, Amy Sanford, Vishal Boolell, Hong Liu, Ayman Samkari, Steven M. Keller, Martin Reck. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer. JAMA Oncology 2021; 7(9): 1351 doi: 10.1001/jamaoncol.2021.2301
|
| 96 |
Lygia Bertalha Yaegashi, Camila Machado Baldavira, Tabatha Gutierrez Prieto, Juliana Machado-Rugolo, Ana Paula Pereira Velosa, Lizandre Keren Ramos da Silveira, Aline Assato, Alexandre Muxfeldt Ab’Saber, Roberto Falzoni, Teresa Takagaki, Pedro Leme Silva, Walcy Rosolia Teodoro, Vera Luiza Capelozzi. In Situ Overexpression of Matricellular Mechanical Proteins Demands Functional Immune Signature and Mitigates Non-Small Cell Lung Cancer Progression. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.714230
|
| 97 |
Jyoti D. Patel, Ju-Whei Lee, David P. Carbone, Henry Wagner, Anil Shanker, Maria Teresa P. de Aquino, Leora Horn, Melissa L. Johnson, David E. Gerber, Jane Jijun Liu, Millie S. Das, Mohammed Ali Al-Nsour, Christopher S.R. Dakhil, Suresh Ramalingam, Joan H. Schiller. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non–Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). Clinical Lung Cancer 2020; 21(6): 520 doi: 10.1016/j.cllc.2020.06.007
|
| 98 |
Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park. Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study). Lung Cancer 2020; 146: 112 doi: 10.1016/j.lungcan.2020.05.033
|
| 99 |
N. V. Marinichenko, K. K. Laktionov, A. V. Nazarenko, E. V. Reutova, Merab S. Ardzinba, V. L. Utkina, T. N. Borisova, A. A. Fedorova, Milada S. Ardzinba. Combination of chemoradiation therapy with immunotherapy in the treatment of patients with inoperable stage III non-small cell lung cancer. Meditsinskiy sovet = Medical Council 2020; (20): 209 doi: 10.21518/2079-701X-2020-20-209-214
|
| 100 |
Suzhen Wang, Huai‐Xin Xing, Jianbin Li, Ying‐Jie Zhang, Ting‐Yong Fan, Shuang‐Hu Yuan, Xu‐Dong Hu, Min Xu. Correlation of displacement of mediastinal metastatic lymph nodes with adjacent organs in non‐small cell lung cancer on four‐dimensional computed tomography. Precision Radiation Oncology 2019; 3(2): 38 doi: 10.1002/pro6.64
|
| 101 |
Alice Spencer, Jenna Williams, Robert Samuel, Ian S. Boon, Katy Clarke, Pooja Jain. Concurrent versus sequential chemoradiotherapy for unresectable locally advanced stage III non-small cell lung cancer: Retrospective analysis in a single United Kingdom cancer centre. Cancer Treatment and Research Communications 2021; 29: 100460 doi: 10.1016/j.ctarc.2021.100460
|
| 102 |
Scott J. Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki H. Lee, Maike de Wit, Byoung C. Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young-Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz-Ares, Javier de Castro Carpeño, Catherine Wadsworth, Giovanni Melillo, Haiyi Jiang, Yifan Huang, Phillip A. Dennis, Mustafa Özgüroğlu. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. New England Journal of Medicine 2017; 377(20): 1919 doi: 10.1056/NEJMoa1709937
|
| 103 |
Juliana Matiello, Alan Dal Pra, Laise Zardo, Ricardo Silva, Danilo C Berton. Impacts of post‐radiotherapy lymphocyte count on progression‐free and overall survival in patients with stage III lung cancer. Thoracic Cancer 2020; 11(11): 3139 doi: 10.1111/1759-7714.13621
|
| 104 |
Julian Taugner, Lukas Käsmann, Chukwuka Eze, Alexander Rühle, Amanda Tufman, Niels Reinmuth, Thomas Duell, Claus Belka, Farkhad Manapov. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients. Investigational New Drugs 2021; 39(4): 1189 doi: 10.1007/s10637-021-01091-9
|
| 105 |
Ana Gómez Rueda, Álvaro Taus, Rosa Álvarez Álvarez, Reyes Bernabé-Caro, Luis Chara, Marta López-Brea, Laia Vilà, Maria Ángeles Sala González, Anabel del Barrio Díaz Aldagalán, Beatriz Esteban Herrera, Rafael López Castro, Ruth Álvarez Cabellos, Marta Doménech, Sandra Falagan, Alberto Moreno Vega, Carlos Aguado, Andrés Barba, Maria Teresa Delgado Ureña, Dolores Isla, Lorena Bellido Hernández, José Luis Fírvida Pérez, Óscar Juan-Vidal, Bartomeu Massutí, Xabier Mielgo-Rubio, Ana Laura Ortega, Silvia Catot, Manuel Dómine, Corina Escoín-Pérez, Francisco García Navalón, Ignacio Gil-Bazo, Silvia Muñoz, Delvys Rodríguez-Abreu, Rosa María Villatoro Roldán, Guillermo Alonso-Jáudenes Curbera, Luis León-Mateos, Airam Padilla, Alfredo Paredes Lario, José Miguel Sánchez-Torres, Pilar Garrido. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Clinical and Translational Oncology 2024; doi: 10.1007/s12094-024-03404-9
|
| 106 |
Yuting Zhan, Hongjing Zang, Juan Feng, Junmi Lu, Lingjiao Chen, Songqing Fan. Long non-coding RNAs associated with non-small cell lung cancer. Oncotarget 2017; 8(40): 69174 doi: 10.18632/oncotarget.20088
|
| 107 |
Oisín Bugter, Dirk L.P. van Iwaarden, Emilie A.C. Dronkers, Martine J. de Herdt, Marjan H. Wieringa, Gerda M. Verduijn, Marc A.M. Mureau, Ivo ten Hove, Esther van Meerten, José A. Hardillo, Robert J. Baatenburg de Jong. Survival of patients with head and neck cancer with metachronous multiple primary tumors is surprisingly favorable. Head & Neck 2019; 41(6): 1648 doi: 10.1002/hed.25595
|
| 108 |
Wei Xiao, Lan Wang, John Howard, Ravindra Kolhe, Amyn M. Rojiani, Mumtaz V. Rojiani. TIMP-1-Mediated Chemoresistance via Induction of IL-6 in NSCLC. Cancers 2019; 11(8): 1184 doi: 10.3390/cancers11081184
|
| 109 |
Jiaqi Han, Kun Tian, Jiangping Yang, Youling Gong. Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis. Lung Cancer 2020; 146: 42 doi: 10.1016/j.lungcan.2020.05.011
|
| 110 |
Georgios Chatzikonstantinou, Nikolaos Zamboglou, Dimos Baltas, Konstantinos Ferentinos, Dimitra Bon, Nikolaos Tselis. Image-guided interstitial high-dose-rate brachytherapy for dose escalation in the radiotherapy treatment of locally advanced lung cancer: A single-institute experience. Brachytherapy 2019; 18(6): 829 doi: 10.1016/j.brachy.2019.08.001
|
| 111 |
Tomohiro Takehara, Tetsuo Tani, Hiroyuki Takiue, Ryo Takeshita, Arifumi Iwamaru, Tatsuya Yamamoto, Hidefumi Koh. Outcome of patients with lung cancer and severe psychiatric disorder admitted to a medical psychiatric unit. Molecular and Clinical Oncology 2020; doi: 10.3892/mco.2020.1974
|
| 112 |
Amaiyya Agrawal, Sankha Bhattacharya. Cutting-edge Nanotechnological Approaches for Lung Cancer Therapy. Current Drug Research Reviews 2022; 14(3): 171 doi: 10.2174/2589977514666220418085658
|
| 113 |
Jayasheela S Hiremath, AHM Viswanath Swamy, Pooja Mahajan, Tejashree Sridhar, Sudhanshu Shukla. A comprehensive review of clinical outcomes and safety profile of durvalumab in non-small cell lung cancer. MGM Journal of Medical Sciences 2024; 11(1): 152 doi: 10.4103/mgmj.mgmj_275_23
|
| 114 |
Chiara Catania, Andrea Riccardo Filippi, Claudia Sangalli, Gaia Piperno, Marco Russano, Carlo Greco, Vieri Scotti, Claudia Proto, Chiara Bennati, Marzia Di Pietro Paolo, Angelo Platania, Emanuela Olmetto, Francesco Agustoni, Nazario Teodorani, Vincenzo Agbaje, Alessandro Russo. New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists – INTERACTION group. Critical Reviews in Oncology/Hematology 2023; 190: 104108 doi: 10.1016/j.critrevonc.2023.104108
|
| 115 |
Anjali K. Pahuja, Kundan Singh Chufal, Irfan Ahmad, Ram Bajpai, Rajpal Singh, Rahul Lal Chowdhary, Maithili Sharma. Identifying Prognostic Groups Using Machine Learning Tools in Patients Undergoing Chemoradiation for Inoperable Locally Advanced Nonsmall Cell Lung Carcinoma. Asian Journal of Oncology 2019; 5: 056 doi: 10.1055/s-0039-3401437
|
| 116 |
Jung Hyun Nam, Chang Dong Yeo, Chan Kwon Park, Sung Kyoung Kim, Ju Sang Kim, Yong Hyun Kim, Jin Woo Kim, Seung Joon Kim, Sang Haak Lee, Hye Seon Kang. Identification of predictive factors for early relapse in patients with unresectable stage III non‐small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy. Thoracic Cancer 2023; 14(26): 2657 doi: 10.1111/1759-7714.15050
|
| 117 |
Yuichiro Takeda, Yusaku Kusaba, Yoko Tsukita, Yukari Uemura, Eisaku Miyauchi, Takaya Yamamoto, Hiroshi Mayahara, Akito Hata, Hidetsugu Nakayama, Satoshi Tanaka, Junji Uchida, Kazuhiro Usui, Tatsuya Toyoda, Motohiro Tamiya, Masahiro Morimoto, Yuko Oya, Takeshi Kodaira, Keiichi Jingu, Hisatoshi Sugiura. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non–small cell lung cancer: A multicenter retrospective cohort study. Clinical and Translational Radiation Oncology 2022; 37: 57 doi: 10.1016/j.ctro.2022.08.010
|
| 118 |
Ming Zhang, Libing Sun, Yi Ru, Shasha Zhang, Junjun Miao, Pengda Guo, Jinghuan Lv, Feng Guo, Biao Liu. A risk score system based on DNA methylation levels and a nomogram survival model for lung squamous cell carcinoma. International Journal of Molecular Medicine 2020; 46(1): 252 doi: 10.3892/ijmm.2020.4590
|
| 119 |
David Waterhouse, Candice Yong, Andrew Frankart, Lance Brannman, Tiernan Mulrooney, Nicholas Robert, Kathleen M Aguilar, Juliet Ndukum, Ion Cotarla. Durvalumab real-world treatment patterns and outcomes in patients with stage III non-small-cell lung cancer treated in a US community setting. Future Oncology 2023; 19(28): 1905 doi: 10.2217/fon-2023-0117
|
| 120 |
Corinne Faivre-Finn, David R. Spigel, Suresh Senan, Corey Langer, Bradford A. Perez, Mustafa Özgüroğlu, Davey Daniel, Augusto Villegas, David Vicente, Rina Hui, Shuji Murakami, Luis Paz-Ares, Helen Broadhurst, Catherine Wadsworth, Phillip A. Dennis, Scott J. Antonia. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Lung Cancer 2021; 151: 30 doi: 10.1016/j.lungcan.2020.11.024
|
| 121 |
Hisashi Tanaka, Shigeru Tanzawa, Toshihiro Misumi, Tomonori Makiguchi, Megumi Inaba, Takeshi Honda, Junya Nakamura, Koji Inoue, Takayuki Kishikawa, Masanao Nakashima, Keiichi Fujiwara, Tadashi Kohyama, Hiroo Ishida, Shoichi Kuyama, Naoki Miyazawa, Tomomi Nakamura, Hiroshi Miyawaki, Naohiro Oda, Nobuhisa Ishikawa, Ryotaro Morinaga, Kei Kusaka, Nobukazu Fujimoto, Yasushi Fukuda, Masayuki Yasugi, Takeshi Tsuda, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Kenshiro Shiraishi, Noriyuki Matsutani, Nobuhiko Seki. A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis. Therapeutic Advances in Medical Oncology 2022; 14: 175883592211427 doi: 10.1177/17588359221142786
|
| 122 |
Yutaka Takahara, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Takashi Sakuma, Kazuaki Nishiki, Keisuke Nakase, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Taku Oikawa, Shiro Mizuno. Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapy. Thoracic Cancer 2022; 13(24): 3451 doi: 10.1111/1759-7714.14704
|
| 123 |
James Kavanaugh, Geoffrey Hugo, Cliff G. Robinson, Michael C. Roach. Anatomical Adaptation—Early Clinical Evidence of Benefit and Future Needs in Lung Cancer. Seminars in Radiation Oncology 2019; 29(3): 274 doi: 10.1016/j.semradonc.2019.02.009
|
| 124 |
Abdul Rahman Jazieh, Huseyin Cem Onal, Daniel Shao-Weng Tan, Ross A. Soo, Kumar Prabhash, Amit Kumar, Reto Huggenberger, Byoung Chul Cho. Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study. Therapeutic Advances in Medical Oncology 2022; 14: 175883592211227 doi: 10.1177/17588359221122720
|
| 125 |
Antoine Desilets, Félix Blanc-Durand, Sally Lau, Taiki Hakozaki, Rui Kitadai, Julie Malo, Wiam Belkaid, Corentin Richard, Meriem Messaoudene, Lena Cvetkovic, Suzanne Kazandjian, Mustapha Tehfe, Marie Florescu, Kevin Jao, Nathalie Daaboul, Scott Owen, Benjamin Shieh, Jason Agulnik, Victor Cohen, Chloé Charbonneau, Nicolas Marcoux, Normand Blais, Natasha B. Leighl, Penelope A. Bradbury, Geoffrey Liu, Frances A. Shepherd, Houda Bahig, Bertrand Routy, Adrian Sacher, Arielle Elkrief. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study. European Journal of Cancer 2021; 142: 83 doi: 10.1016/j.ejca.2020.10.008
|
| 126 |
Jie Zhang, Yang Hong, Liang Wang, Weiheng Hu, Guangming Tian, Di Wu, Yang Wang, Ling Dai, Ziran Zhang, Yue Yang, Jian Fang. Aneuploid subtypes of circulating tumor cells and circulating tumor-derived endothelial cells predict the overall survival of advanced lung cancer. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.829054
|
| 127 |
Sanjay Popat, Neal Navani, Keith M. Kerr, Egbert F. Smit, Timothy J.P. Batchelor, Paul Van Schil, Suresh Senan, Fiona McDonald. Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach. The Oncologist 2021; 26(2): e306 doi: 10.1002/onco.13586
|
| 128 |
Andrew J. Plodkowski, Jose Arimateia Batista Araujo-Filho, Cameron D.A. Simmers, Jeffrey Girshman, Micheal Raj, Junting Zheng, Andreas Rimner, Michelle S. Ginsberg. Pre-treatment CT imaging in stage IIIA lung cancer: Can we predict local recurrence after definitive chemoradiotherapy?. Clinical Imaging 2021; 69: 133 doi: 10.1016/j.clinimag.2020.07.005
|
| 129 |
Gokcen Ömeroğlu Şimşek, Pınar Çelik, James R. Jett. Airway diseases. 2023; : 1 doi: 10.1007/978-3-031-22483-6_64-1
|
| 130 |
O. Ercelep, O. Alan, D. Sahin, T. A. Telli, H. Salva, T. B. Tuylu, N. A. Babacan, S. Kaya, F. Dane, T. Ones, H. Alkis, M. Adli, F. Yumuk. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer. Clinical and Translational Oncology 2019; 21(4): 499 doi: 10.1007/s12094-018-1949-6
|
| 131 |
Tharcisio Citrangulo Tortelli, Rodrigo Esaki Tamura, Mara de Souza Junqueira, Janio da Silva Mororó, Silvina Odete Bustos, Renato Jose Mendonça Natalino, Shonagh Russell, Laurent Désaubry, Bryan Eric Strauss, Roger Chammas. Metformin-induced chemosensitization to cisplatin depends on P53 status and is inhibited by Jarid1b overexpression in non-small cell lung cancer cells. Aging 2021; 13(18): 21914 doi: 10.18632/aging.203528
|
| 132 |
Xuchun Liu, Gengyun Sun. Shikonin enhances Adriamycin antitumor effects by inhibiting efflux pumps in A549 cells. Oncology Letters 2017; 14(4): 4270 doi: 10.3892/ol.2017.6702
|
| 133 |
Jyoti D. Patel, Steven J. Chmura. Is immune checkpoint inhibition part of standard therapy for stage III non‐small cell lung cancer?. Cancer 2018; 124(14): 2878 doi: 10.1002/cncr.31557
|
| 134 |
Fei Gao, Lin Jia, Jianjun Han, Yun Wang, Wenjuan Luo, Yan Zeng. Circ-ZNF124 downregulation inhibits non-small cell lung cancer progression partly by inactivating the Wnt/β-catenin signaling pathway via mediating the miR-498/YES1 axis. Anti-Cancer Drugs 2021; 32(3): 257 doi: 10.1097/CAD.0000000000001014
|
| 135 |
Martina Vrankar, Karmen Stanic, Stasa Jelercic, Eva Ciric, Ana Lina Vodusek, Jasna But-Hadzic. Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience. Radiology and Oncology 2021; 55(4): 482 doi: 10.2478/raon-2021-0044
|
| 136 |
Soomin Lee, Julip Jung, Helen Hong, Bong-Seog Kim. Prediction of Two-Year Recurrence-Free Survival in Operable NSCLC Patients Using Radiomic Features from Intra- and Size-Variant Peri-Tumoral Regions on Chest CT Images. Diagnostics 2022; 12(6): 1313 doi: 10.3390/diagnostics12061313
|
| 137 |
Yilin Yu, Zhiping Wang, Qunhao Zheng, Jiancheng Li. FAM72 serves as a biomarker of poor prognosis in human lung adenocarcinoma. Aging 2021; 13(6): 8155 doi: 10.18632/aging.202625
|
| 138 |
Jessica N. LeClair, Man Yee Merl, Michael Cohenuram, Darren Luon. Real-World Incidence of Pneumonitis in Patients Receiving Durvalumab. Clinical Lung Cancer 2022; 23(1): 34 doi: 10.1016/j.cllc.2021.08.006
|
| 139 |
Martin Faehling, Christian Schumann, Petros Christopoulos, Petra Hoffknecht, Jürgen Alt, Marlitt Horn, Stephan Eisenmann, Anke Schlenska-Lange, Philipp Schütt, Felix Steger, Wolfgang M. Brückl, Daniel C. Christoph. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). Lung Cancer 2020; 150: 114 doi: 10.1016/j.lungcan.2020.10.006
|
| 140 |
Jhanelle E. Gray, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Byoung Chul Cho, David Planchard, Luis Paz-Ares, Corinne Faivre-Finn, Johan F. Vansteenkiste, David R. Spigel, Catherine Wadsworth, Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu, Scott J. Antonia. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC. Journal of Thoracic Oncology 2020; 15(2): 288 doi: 10.1016/j.jtho.2019.10.002
|
| 141 |
Beatrice T. B. Preti, Michael S. Sanatani, Daniel Breadner, Suganija Lakkunarajah, Carolyn Scott, Caroline Esmonde-White, Eric McArthur, George Rodrigues, Mitali Chaudhary, Adam Mutsaers, Robin Sachdeva, Mark D. Vincent. Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer. Current Oncology 2023; 30(8): 7713 doi: 10.3390/curroncol30080559
|
| 142 |
Yufan Yang, Tao Zhang, Zongmei Zhou, Jun Liang, Dongfu Chen, Qinfu Feng, Zefen Xiao, Zhouguang Hui, Jima Lv, Lei Deng, Xin Wang, Wenqing Wang, Jianyang Wang, Wenyang Liu, Yirui Zhai, Jie Wang, Nan Bi, Luhua Wang. Development and validation of a prediction model using molecular marker for long‐term survival in unresectable stage III non‐small cell lung cancer treated with chemoradiotherapy. Thoracic Cancer 2022; 13(3): 296 doi: 10.1111/1759-7714.14218
|
| 143 |
Saber A. Amin, Michael J. Baine, Ibur Rahman, Chi Lin. The Association of Immunotherapy With the Overall Survival of Inoperable Stage III Non-small Cell Lung Cancer Patients Who Do Not Receive Chemoradiation. Journal of Immunotherapy 2023; 46(1): 14 doi: 10.1097/CJI.0000000000000443
|
| 144 |
Rina Hui, Mustafa Özgüroğlu, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Jhanelle E Gray, Anna Rydén, Louis Viviers, Lynne Poole, Yiduo Zhang, Phillip A Dennis, Scott J Antonia. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. The Lancet Oncology 2019; 20(12): 1670 doi: 10.1016/S1470-2045(19)30519-4
|
| 145 |
Giovanni Melillo, Vikram Chand, Alejandro Yovine, Ashok Gupta, Cristian Massacesi. Curative-Intent Treatment with Durvalumab in Early-Stage Cancers. Advances in Therapy 2021; 38(6): 2759 doi: 10.1007/s12325-021-01675-0
|
| 146 |
Hsiu-Ying Hung, Yen-Han Tseng, Heng-Sheng Chao, Chao-Hua Chiu, Wen-Hu Hsu, Han-Shui Hsu, Yu-Chung Wu, Teh-Ying Chou, Chun-Ku Chen, Keng-Li Lan, Yi-Wei Chen, Yuan-Hung Wu, Yuh-Min Chen, Stephen Chun. Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer. PLOS ONE 2020; 15(10): e0236503 doi: 10.1371/journal.pone.0236503
|
| 147 |
Leilei Wu, Bo Cheng, Xiaojiang Sun, Zhenshan Zhang, Jingjing Kang, Yun Chen, Qinghua Xu, Shuangyan Yang, Yujie Yan, Shengxiang Ren, Caicun Zhou, Yaping Xu. Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non‐small cell lung cancer: a multi‐institutional retrospective cohort study. MedComm 2024; 5(3) doi: 10.1002/mco2.501
|
| 148 |
Ziyi Wang, Xinyu Zhang, Xuedong Zhang, Xuedong Jiang, Wenya Li. Long Noncoding RNA LINC01703 Exacerbates the Malignant Properties of Non-Small Cell Lung Cancer by Upregulating MACC1 in a MicroRNA-605-3p-Mediated Manner. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 2021; 28(9): 913 doi: 10.3727/096504021X16310057751016
|
| 149 |
Ravi Rajaram, Arlene M. Correa, Ting Xu, Quynh-Nhu Nguyen, Mara B. Antonoff, David Rice, Reza Mehran, Jack Roth, Garrett Walsh, Stephen Swisher, Wayne L. Hofstetter, Ara Vaporciyan, Tina Cascone, Anne S. Tsao, Vassiliki A. Papadimitrakopoulou, Saumil Gandhi, Zhongxing Liao, Boris Sepesi. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non–Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clinical Lung Cancer 2020; 21(4): e294 doi: 10.1016/j.cllc.2020.01.009
|
| 150 |
Ranee Mehra, Candice Yong, Brian Seal, Marjolijn van Keep, Angie Raad, Yiduo Zhang. Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective. Journal of the National Comprehensive Cancer Network 2021; 19(2): 153 doi: 10.6004/jnccn.2020.7621
|
| 151 |
Fotis Nikolos, Christoforos Thomas, Igor Bado, Jan-Åke Gustafsson. ERβ Sensitizes NSCLC to Chemotherapy by Regulating DNA Damage Response. Molecular Cancer Research 2018; 16(2): 233 doi: 10.1158/1541-7786.MCR-17-0201
|
| 152 |
Giulia Veronesi, Bernard Park, Robert Cerfolio, Mark Dylewski, Alpert Toker, Jacques P Fontaine, Wael C Hanna, Emanuela Morenghi, Pierluigi Novellis, Frank O Velez-Cubian, Marisa H Amaral, Elisa Dieci, Marco Alloisio, Eric M Toloza. Robotic resection of Stage III lung cancer: an international retrospective study†. European Journal of Cardio-Thoracic Surgery 2018; 54(5): 912 doi: 10.1093/ejcts/ezy166
|
| 153 |
Tadashi Sakaguchi, Kentaro Ito, Kazuki Furuhashi, Yuki Nakamura, Yuta Suzuki, Yoichi Nishii, Osamu Taguchi, Osamu Hataji. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria. Respiratory Investigation 2019; 57(5): 466 doi: 10.1016/j.resinv.2019.03.011
|
| 154 |
J.B. Adizie, A. Khakwani, P. Beckett, N. Navani, D. West, I. Woolhouse, S.V. Harden. Stage III Non-small Cell Lung Cancer Management in England. Clinical Oncology 2019; 31(10): 688 doi: 10.1016/j.clon.2019.07.020
|
| 155 |
Bo-Yi Li, Yi Luo, Wen-Si Zhao, Lu Zhang, Han-Jing Zhou, Yu-Chun Zou, Tao Zhang. MicroRNA-210 negatively regulates the radiosensitivity of nasopharyngeal carcinoma cells. Molecular Medicine Reports 2017; 16(2): 1401 doi: 10.3892/mmr.2017.6694
|
| 156 |
Shubing Jia, Jian Chen, Ningyi Ma, Jingfang Zhao, Jingfang Mao, Guoliang Jiang, Jiade Lu, Kailiang Wu. Adaptive carbon ion radiotherapy for locally advanced non‐small cell lung cancer: Organ‐sparing potential and target coverage. Medical Physics 2022; 49(6): 3980 doi: 10.1002/mp.15563
|
| 157 |
S. Peters, E. Felip, U. Dafni, C. Belka, M. Guckenberger, A. Irigoyen, E. Nadal, A. Becker, H. Vees, M. Pless, A. Martinez-Marti, A. Tufman, M. Lambrecht, N. Andratschke, A.C. Piguet, M. Kassapian, H. Roschitzki-Voser, M. Rabaglio-Poretti, R.A. Stahel, J. Vansteenkiste, D. De Ruysscher. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial. Lung Cancer 2019; 133: 83 doi: 10.1016/j.lungcan.2019.05.001
|
| 158 |
Patrizio Armeni, Ludovica Borsoi, Giulia Fornaro, Claudio Jommi, Francesco Grossi, Francesco Costa. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non–small Cell Lung Cancer in the Italian National Health Service. Clinical Therapeutics 2020; 42(5): 830 doi: 10.1016/j.clinthera.2020.03.012
|
| 159 |
Nicolas Girard, Jair Bar, Pilar Garrido, Marina C. Garassino, Fiona McDonald, Françoise Mornex, Andrea R. Filippi, Hans J.M. Smit, Solange Peters, John K. Field, Daniel C. Christoph, Anne Sibille, Rainer Fietkau, Vilde D. Haakensen, Christos Chouaid, Ben Markman, T. Jeroen N. Hiltermann, Alvaro Taus, William Sawyer, Allison Allen, Pratibha Chander, Muriel Licour, Benjamin Solomon. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. Journal of Thoracic Oncology 2023; 18(2): 181 doi: 10.1016/j.jtho.2022.10.003
|
| 160 |
Meghan J. Mooradian, Ling Cai, Alice Wang, Yao Qiao, Pratibha Chander, Ryan M. Whitaker. Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non–Small Cell Lung Cancer. JAMA Network Open 2024; 7(4): e247542 doi: 10.1001/jamanetworkopen.2024.7542
|
| 161 |
Fang Cui, Peng Luo, Yao Bai, Jiangping Meng. Silencing of Long Non-Coding RNA FGD5-AS1 Inhibits the Progression of Non-Small Cell Lung Cancer by Regulating the miR-493-5p/DDX5 Axis. Technology in Cancer Research & Treatment 2021; 20: 153303382199000 doi: 10.1177/1533033821990007
|
| 162 |
RUI ZHOU, JIANYANG XU, LINGWEI WANG, JIANXIN LI. LncRNA PRRT3-AS1 exerts oncogenic effects on nonsmall cell lung cancer by targeting microRNA-507/homeobox B5 axis. Oncology Research 2021; 29(6): 411 doi: 10.32604/or.2022.026236
|
| 163 |
Lærke Rosenlund Nielsen, Simone Stensgaard, Peter Meldgaard, Boe Sandahl Sorensen. ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach. Cancer Treatment and Research Communications 2024; 39: 100802 doi: 10.1016/j.ctarc.2024.100802
|
| 164 |
Shi Tang, Xiaofeng Cong, Dan Zheng, Chen Chen, Zengguang Liu, Jie Gao, Huimin Zhang, Youhao Zhang, Ziling Liu. Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1129989
|
| 165 |
Shigeru Tanzawa, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Toshihiro Misumi, Kenshiro Shiraishi, Noriyuki Matsutani, Hisashi Tanaka, Megumi Inaba, Terunobu Haruyama, Junya Nakamura, Takayuki Kishikawa, Masanao Nakashima, Keiichi Iwasa, Keiichi Fujiwara, Tadashi Kohyama, Shoichi Kuyama, Naoki Miyazawa, Tomomi Nakamura, Hiroshi Miyawaki, Hiroo Ishida, Naohiro Oda, Nobuhisa Ishikawa, Ryotaro Morinaga, Kei Kusaka, Nobukazu Fujimoto, Toshihide Yokoyama, Kenichi Gemba, Takeshi Tsuda, Hideyuki Nakagawa, Hirotaka Ono, Tetsuo Shimizu, Morio Nakamura, Sojiro Kusumoto, Ryuji Hayashi, Hiroki Shirasaki, Nobuaki Ochi, Keisuke Aoe, Nobuhiro Kanaji, Kosuke Kashiwabara, Hiroshi Inoue, Nobuhiko Seki. A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study). Therapeutic Advances in Medical Oncology 2021; 13: 175883592199858 doi: 10.1177/1758835921998588
|
| 166 |
Wenjie Wu, Siyu Zhu, Yonghui Wu, Lu Dai, Jian Zhao, Zeyong Jiang. Long intergenic non-protein-coding RNA 1547 acts as a competing endogenous RNA and exerts cancer-promoting activity in non-small cell lung cancer by targeting the microRNA-195-5p/ homeobox C8 axis. Heliyon 2023; 9(8): e18015 doi: 10.1016/j.heliyon.2023.e18015
|
| 167 |
Yuko Tsuchiya-Kawano, Tomonari Sasaki, Hiroyuki Yamaguchi, Katsuya Hirano, Atsushi Horiike, Miyako Satouchi, Shinobu Hosokawa, Ryotaro Morinaga, Kazutoshi Komiya, Koji Inoue, Yuka Fujita, Ryo Toyozawa, Tomoki Kimura, Kosuke Takahashi, Kazuo Nishikawa, Junji Kishimoto, Yoichi Nakanishi, Isamu Okamoto. Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer. The Oncologist 2020; 25(6): 475 doi: 10.1634/theoncologist.2019-0746
|
| 168 |
Ion Cotarla, Marnie L. Boron, Shawna L. Cullen, Daryl S. Spinner, Eric C. Faulkner, Marissa C. Carroll, Surbhi Shah, Adam Yagui-Beltran. Treatment Decision Drivers in Stage III Non–Small-Cell Lung Cancer: Outcomes of a Web-Based Survey of Oncologists in the United States. JCO Oncology Practice 2020; 16(10): e1232 doi: 10.1200/JOP.19.00781
|
| 169 |
Andrew Hope, Maikel Verduin, Thomas J Dilling, Ananya Choudhury, Rianne Fijten, Leonard Wee, Hugo JWL Aerts, Issam El Naqa, Ross Mitchell, Marc Vooijs, Andre Dekker, Dirk de Ruysscher, Alberto Traverso. Artificial Intelligence Applications to Improve the Treatment of Locally Advanced Non-Small Cell Lung Cancers. Cancers 2021; 13(10): 2382 doi: 10.3390/cancers13102382
|
| 170 |
Mitsue Kawamura, Norio Araki, Noriko Kishi, Tatsuya Suwa, Yuki Yamamoto, Osamu Kanai, Kohei Fujita, Misato Okamura, Koichi Nakatani, Tadashi Mio. Retrospective Treatment Outcomes of Concurrent Chemoradiotherapy in Patients with Stage III Non-small Cell Lung Cancer at a Single Institution: The Pre-PACIFIC Era. Haigan 2021; 61(5): 383 doi: 10.2482/haigan.61.383
|